百利天恒: 四川百利天恒药业股份有限公司自愿披露关于iza-bren（EGFR×HER3双抗ADC）用于铂耐药复发上皮性卵巢癌III期临床试验完成首例受试者入组的公告

Group 1 - The company has completed the enrollment of the first subject in the Phase III clinical trial for its first-in-class drug, Iza-bren, targeting platinum-resistant recurrent epithelial ovarian cancer [1] - Iza-bren is the only EGFR×HER3 dual antibody ADC that has entered Phase III clinical trials globally [1] - The drug is currently involved in over 40 clinical trials in China and the United States for various tumor types, including non-small cell lung cancer, small cell lung cancer, breast cancer, nasopharyngeal carcinoma, esophageal squamous cell carcinoma, and urothelial carcinoma [2]